HNSA Hansa Biopharma AB (publ)

4.451USD45.14 SEK · STO-4.61%Mkt Cap: 443.94M USDP/E: —

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company…

Institutional holders4 on file

Key Statistics

Company
Market Cap443.94M USD
Enterprise Value414.62M USD
Revenue (TTM)29.74M USD
Gross Profit13.68M USD
Net Income (TTM)-52.67M USD
Revenue/Share0.29 USD
Last Price4.451 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees111
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0002148817
Valuation
P/E (Trailing)—
P/E (Forward)-6.12
PEG—
EV/EBITDA-7.24
EV/Revenue13.94
P/S14.92
P/B-6.70
EPS (TTM)-0.78 USD
EPS (Forward)-0.73 USD
52W Range
2.31977% of range5.093
52W High5.093 USD
52W Low2.319 USD
Profitability
Gross Margin62.41%
Oper. Margin-195.31%
EBITDA Margin-192.54%
Profit Margin-240.30%
ROE600.18%
ROA-45.78%
ROIC-348.45%
ROCE-68.48%
Growth
Revenue Growth364.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.15M USD
CapEx (TTM)—
FCF Margin37.27%
FCF Yield2.50%
Net Debt-38.35M USD
Net Debt/EBITDA0.67
Net Debt/FCF-3.46
Balance Sheet
Debt/Equity-10.55
Current Ratio1.62
Quick Ratio1.61
Book Value/Sh-0.66 USD
Cash/Share1.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.100 USD
Upside (mean)+59.5%
Target Range3.550 USD – 10.16 USD
3.550+59.5% to mean10.16
# Analysts8
Ownership
Shares Out.99.73M
Float65.75M
Insiders5.72%
Institutions48.83%
Technical
SMA 503.736 (+19.1%)
SMA 2003.426 (+29.9%)
Beta1.68
S&P 52W Chg8.68%
Avg Vol (30d)755.48K
Avg Vol (10d)1.44M
Technical Indicators
RSI (14)59.2
MACD2.7405
MACD Signal2.2831
MACD Hist.+0.4574
BB Upper5.007 USD
BB Middle4.152 USD
BB Lower3.297 USD
BB Width41.19%
ATR (14)0.2624 USD
Vol Ratio (20d)0.73x

About Hansa Biopharma (STO: HNSA)

›

Hansa Biopharma (STO: HNSA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 111 employees.

The shares were at 45.14 SEK on 20 November 2026, up 67.4% over 52 weeks. Its 52-week range is 23.52 SEK to 51.65 SEK: the price is 12.6% below the high and 91.9% above the low.

Its market capitalisation is 4.50B SEK.

Hansa Biopharma reports an operating margin of -195.3% and revenue up 364.2% year over year.

It holds more cash than debt, a net cash position of 388.90M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 72.00 SEK is 59.5% above the current price. The next earnings report is expected on 11 February 2027.